Cell Source, Inc. (CLCS)
Develops immune cells that help transplants and stem cell treatments succeed by suppressing rejection
$0.65+0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago+110.2%
The outlook
CLCS is trading near its 52-week low, well below both its 50- and 200-day moving averages, signaling a sustained downtrend. Analyst coverage appears minimal, and the StockGlow score sits firmly in bearish territory at 14/100. The stock is positioned in the lower portion of its annual trading range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range18% of the way from its 52-week low to high
Market cap
$44.2M
52-wk high
$2.25
52-wk low
$0.30
50-day avg
$0.81
200-day avg
$0.71
Trailing P/E
—